Literature DB >> 10738302

Mutation screening of the CDKN2A promoter in melanoma families.

M Harland1, E A Holland, P Ghiorzo, M Mantelli, G Bianchi-Scarrà, A M Goldstein, M A Tucker, B A Ponder, G J Mann, D T Bishop, J Newton Bishop.   

Abstract

Germline mutations of CDKN2A, at 9p21, are responsible for predisposition to melanoma in some families. However, evidence of linkage to 9p21 has been demonstrated in a significant proportion of kindreds with no detectable mutations in CDKN2A. It is possible that mutations in noncoding regions may be responsible for predisposition to melanoma in these families. We have analyzed approximately 1 kb of the CDKN2A promoter upstream of the start codon in an attempt to identify causal mutations in 107 melanoma families. Four sequence variants were detected. Two of these (A-191G and A-493T) did not segregate with disease and were present in a control population at a comparable frequency, indicating that they are unlikely to predispose to melanoma. The A-493T variant appeared to be in linkage disequilibrium with the previously described CDKN2A polymorphism Ala148Thr. The variant G-735A was detected in the control population, but segregation of this variant with melanoma within families could not be discounted. The fourth variant (G-34T), located in the 5' UTR, creates an aberrant initiation codon. This variant appeared to segregate with melanoma and was not detected in a control population. G-34T has recently been identified in a subset of Canadian melanoma families and was concluded to be associated with predisposition to melanoma. The creation of an aberrant initiation site in the 5' UTR may have an important role in carcinogenesis in a small percentage of families; however, mutations in the CDKN2A promoter appear to have a limited role in predisposition to melanoma. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10738302

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  14 in total

1.  Two common forms of the human MLH1 gene may be associated with functional differences.

Authors:  P Hutter; A Couturier; C Rey-Berthod
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

2.  Localization of a novel melanoma susceptibility locus to 1p22.

Authors:  Elizabeth Gillanders; Suh-Hang Hank Juo; Elizabeth A Holland; MaryPat Jones; Derek Nancarrow; Diana Freas-Lutz; Raman Sood; Naeun Park; Mezbah Faruque; Carol Markey; Richard F Kefford; Jane Palmer; Wilma Bergman; D Timothy Bishop; Margaret A Tucker; Brigitte Bressac-de Paillerets; Johan Hansson; Mitchell Stark; Nelleke Gruis; Julia Newton Bishop; Alisa M Goldstein; Joan E Bailey-Wilson; Graham J Mann; Nicholas Hayward; Jeffrey Trent
Journal:  Am J Hum Genet       Date:  2003-07-03       Impact factor: 11.025

3.  Biallelic mutations in p16(INK4a) confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts.

Authors:  Thomas J Huot; Janice Rowe; Mark Harland; Sarah Drayton; Sharon Brookes; Chandra Gooptu; Patricia Purkis; Mike Fried; Veronique Bataille; Eiji Hara; Julia Newton-Bishop; Gordon Peters
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

4.  CDKN2A and MC1R variants found in Cypriot patients diagnosed with cutaneous melanoma.

Authors:  Georgia Koulermou; Christos Shammas; Andreas Vassiliou; Tassos C Kyriakides; Constantina Costi; Vassos Neocleous; Leonidas A Phylactou; Maria Pantelidou
Journal:  J Genet       Date:  2017-03       Impact factor: 1.166

5.  Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.

Authors:  Alisa M Goldstein; May Chan; Mark Harland; Nicholas K Hayward; Florence Demenais; D Timothy Bishop; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarra; William Bruno; Donato Calista; Lisa A Cannon Albright; Valerie Chaudru; Agnes Chompret; Francisco Cuellar; David E Elder; Paola Ghiorzo; Elizabeth M Gillanders; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M MacKie; Veronica Magnusson; Graham J Mann; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

6.  Differential effects of genes of the Rb1 signalling pathway on osteosarcoma incidence and latency in alpha-particle irradiated mice.

Authors:  Iria Gonzalez-Vasconcellos; Tanja Domke; Virginija Kuosaite; Irene Esposito; Bahar Sanli-Bonazzi; Michaela Nathrath; Michael J Atkinson; Michael Rosemann
Journal:  Radiat Environ Biophys       Date:  2010-11-10       Impact factor: 1.925

7.  A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL).

Authors:  Mark Harland; Alisa M Goldstein; Kairen Kukalizch; Claire Taylor; David Hogg; Susana Puig; Celia Badenas; Nelleke Gruis; Jeanet ter Huurne; Wilma Bergman; Nicholas K Hayward; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Maria Teresa Landi; Giovanna Bianchi Scarra; Paola Ghiorzo; Peter A Kanetsky; David Elder; Graham J Mann; Elizabeth A Holland; D Timothy Bishop; Julia Newton Bishop
Journal:  Eur J Cancer       Date:  2008-04-03       Impact factor: 9.162

8.  Polymorphisms in promoter sequences of MDM2, p53, and p16 genes in normal Japanese individuals.

Authors:  Yasuhito Ohsaka; Hoyoku Nishino
Journal:  Genet Mol Biol       Date:  2010-12-01       Impact factor: 1.771

9.  A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.

Authors:  Satoru Yokoyama; Susan L Woods; Glen M Boyle; Lauren G Aoude; Stuart MacGregor; Victoria Zismann; Michael Gartside; Anne E Cust; Rizwan Haq; Mark Harland; John C Taylor; David L Duffy; Kelly Holohan; Ken Dutton-Regester; Jane M Palmer; Vanessa Bonazzi; Mitchell S Stark; Judith Symmons; Matthew H Law; Christopher Schmidt; Cathy Lanagan; Linda O'Connor; Elizabeth A Holland; Helen Schmid; Judith A Maskiell; Jodie Jetann; Megan Ferguson; Mark A Jenkins; Richard F Kefford; Graham G Giles; Bruce K Armstrong; Joanne F Aitken; John L Hopper; David C Whiteman; Paul D Pharoah; Douglas F Easton; Alison M Dunning; Julia A Newton-Bishop; Grant W Montgomery; Nicholas G Martin; Graham J Mann; D Timothy Bishop; Hensin Tsao; Jeffrey M Trent; David E Fisher; Nicholas K Hayward; Kevin M Brown
Journal:  Nature       Date:  2011-11-13       Impact factor: 49.962

10.  Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.

Authors:  N Soufir; J J Lacapere; G Bertrand; E Matichard; R Meziani; D Mirebeau; V Descamps; B Gérard; A Archimbaud; L Ollivaud; F Bouscarat; M Baccard; G Lanternier; P Saïag; C Lebbé; N Basset-Seguin; B Crickx; H Cave; B Grandchamp
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.